Oppenheimer Asset Management Inc. Cuts Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Oppenheimer Asset Management Inc. decreased its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 53.4% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,771 shares of the medical instruments supplier's stock after selling 6,601 shares during the period. Oppenheimer Asset Management Inc.'s holdings in LeMaitre Vascular were worth $536,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of the company. NBC Securities Inc. increased its position in shares of LeMaitre Vascular by 73.2% during the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier's stock valued at $40,000 after acquiring an additional 183 shares during the last quarter. GAMMA Investing LLC increased its position in shares of LeMaitre Vascular by 57.0% during the 2nd quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier's stock valued at $45,000 after purchasing an additional 199 shares during the last quarter. USA Financial Formulas bought a new stake in shares of LeMaitre Vascular during the 3rd quarter worth $60,000. West Oak Capital LLC bought a new stake in shares of LeMaitre Vascular during the 2nd quarter worth $58,000. Finally, nVerses Capital LLC grew its position in LeMaitre Vascular by 33.3% during the second quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier's stock valued at $66,000 after buying an additional 200 shares during the period. Institutional investors own 84.64% of the company's stock.

Analyst Upgrades and Downgrades

LMAT has been the topic of several research reports. Oppenheimer reaffirmed an "outperform" rating and issued a $93.00 price objective (up previously from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Barrington Research upped their price objective on LeMaitre Vascular from $92.00 to $93.00 and gave the company an "outperform" rating in a research note on Friday, November 1st. Cantor Fitzgerald began coverage on LeMaitre Vascular in a report on Tuesday, October 15th. They set a "neutral" rating and a $96.00 price objective for the company. JMP Securities upped their price target on LeMaitre Vascular from $77.00 to $100.00 and gave the company a "market outperform" rating in a research report on Tuesday, August 20th. Finally, Lake Street Capital initiated coverage on LeMaitre Vascular in a report on Friday, August 2nd. They issued a "buy" rating and a $105.00 price objective for the company. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $94.57.

LeMaitre Vascular Stock Performance

NASDAQ LMAT traded down $0.30 during trading hours on Wednesday, hitting $103.44. The company had a trading volume of 97,400 shares, compared to its average volume of 123,983. The firm has a market capitalization of $2.33 billion, a price-to-earnings ratio of 56.52, a PEG ratio of 2.50 and a beta of 0.89. LeMaitre Vascular, Inc. has a 52 week low of $51.70 and a 52 week high of $106.49. The firm has a 50 day simple moving average of $92.80 and a 200 day simple moving average of $86.35.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, beating analysts' consensus estimates of $0.44 by $0.05. The company had revenue of $54.82 million during the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. LeMaitre Vascular's revenue was up 15.6% compared to the same quarter last year. During the same period last year, the business earned $0.33 earnings per share. On average, research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st will be paid a $0.16 dividend. The ex-dividend date is Thursday, November 21st. This represents a $0.64 dividend on an annualized basis and a yield of 0.62%. LeMaitre Vascular's dividend payout ratio is currently 34.97%.

Insider Buying and Selling at LeMaitre Vascular

In other news, Director Bridget A. Ross sold 3,750 shares of the firm's stock in a transaction on Friday, November 15th. The shares were sold at an average price of $101.47, for a total transaction of $380,512.50. Following the sale, the director now owns 2,278 shares in the company, valued at approximately $231,148.66. This trade represents a 62.21 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 10.79% of the company's stock.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.